Yamo Pharmaceuticals
Categories
PharmaceuticalsDescription
Yamo Pharmaceuticals is developing L1-79, a novel therapy that targets the core symptoms of autism and has been well-tolerated by clinical trial patients to-date. The mechanism of action for L1-79 addresses both the central nervous system and metabolic symptoms of autism.
Business Overview
Directions to listing
Disclaimer
The Ohio Life Sciences Directory is provided by Ohio Life Sciences for the purpose of promoting life sciences-related organizations in Ohio. Profiles are based on publicly available and company-provided information. Ohio Life Sciences is a member supported organization, therefore members are prioritized in search results and receive special logo visibility, but non-members are included. Members may request a targeted, staff-generated offline search of the Directory. Ohio Life Sciences works to keep the Directory up to date, however, as details may change without notice, users should always refer to the listed organization directly for current information. Placement of a Directory listing does not represent an endorsement or testimony from Ohio Life Sciences as to the quality/validity of the products/services listed. Ohio Life Sciences retains exclusive management of OhioLifeSciences.org content and reserves the right to accept, reject, or remove listings on the Ohio Life Sciences website at any time. Questions? Want to update or list your organization? Please visit our contact page.